CHO-K1/Human GLP-2 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0107A | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The glucagon-like peptide-2 receptor (GLP-2R) is a class B G protein-coupled receptor that specifically binds the gut hormone GLP-2. It is primarily distributed throughout the intestinal tract (small and large intestine) in epithelial cells, particularly within crypt and villus regions, with minor expression in the central nervous system. Its core function is to potently stimulate intestinal mucosal epithelial cell proliferation, inhibit apoptosis, enhance gut barrier function, and improve intestinal blood flow and nutrient absorption, thereby playing a crucial role in intestinal protection, repair, and adaptation. As a key regulator of intestinal health, GLP-2R-based analogs (e.g., teduglutide) have become the standard treatment for short bowel syndrome and show therapeutic potential for conditions like Crohn's disease.
Screeningbio’s CHO-K1/Human GLP-2 cell line overexpress GLP1R and is designed to detect increases in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | GLP2R |
Accession Number | NM_004246 (Hs) |
Parental Line | CHO-K1 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The glucagon-like peptide-2 receptor (GLP-2R) is a class B G protein-coupled receptor that specifically binds the gut hormone GLP-2. It is primarily distributed throughout the intestinal tract (small and large intestine) in epithelial cells, particularly within crypt and villus regions, with minor expression in the central nervous system.
Its core function is to potently stimulate intestinal mucosal epithelial cell proliferation, inhibit apoptosis, enhance gut barrier function, and improve intestinal blood flow and nutrient absorption, thereby playing a crucial role in intestinal protection, repair, and adaptation.
As a key regulator of intestinal health, GLP-2R-based analogs (e.g., teduglutide) have become the standard treatment for short bowel syndrome and show therapeutic potential for conditions like Crohn's disease.